Streetbeat News

Analyst Ratings

IBKR

Barclays analyst Benjamin Budish maintains an Overweight rating on Interactive Brokers Group (NASDAQ:IBKR) but slightly lowers the price target from $166 to $165.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 7:56 pm

GS

Barclays analyst Jason Goldberg has maintained an Overweight rating on Goldman Sachs Group (NYSE:GS) and raised the price target from $565 to $588.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 7:55 pm

COTY

Barclays analyst Lauren Lieberman has maintained an Equal-Weight rating on Coty (NYSE:COTY) but has lowered the price target from $10 to $8.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 7:53 pm

C

Barclays analyst Jason Goldberg maintains an Equal-Weight rating on Citigroup and raises the price target from $63 to $70.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 7:52 pm

WFRD

Barclays analyst David Anderson maintains an Overweight rating on Weatherford International but lowers the price target from $165 to $154.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 7:50 pm

SLB

Barclays analyst David Anderson maintains an Overweight rating on Schlumberger (NYSE:SLB) but lowers the price target from $67 to $63.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 7:49 pm

PUMP

Barclays analyst David Anderson maintains an Overweight rating on ProPetro Holding (NYSE:PUMP) but lowers the price target from $13 to $12.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 7:47 pm

PTEN

Barclays analyst David Anderson maintains an Overweight rating on Patterson-UTI Energy but lowers the price target from $14 to $12.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 7:46 pm

INDP

Indaptus Therapeutics shares are experiencing an increase in trading value following HC Wainwright & Co.'s decision to reiterate a Buy rating on the stock.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 7:45 pm

NOV

Barclays analyst David Anderson has maintained an Underweight rating on NOV and lowered the price target from $20 to $17.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 7:45 pm